Equities

Consun Pharmaceutical Group Ltd

Consun Pharmaceutical Group Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)6.19
  • Today's Change0.16 / 2.65%
  • Shares traded11.27m
  • 1 Year change+23.80%
  • Beta0.5866
Data delayed at least 15 minutes, as of Sep 20 2024 09:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Consun Pharmaceutical Group Ltd is a company principally engaged in manufacturing and sales of pharmaceutical products. The Company operates its businesses through two segments. Consun Pharmaceutical segment is mainly engaged in manufacturing and sells of modern Chinese medicines and medical contrast medium. Yulin Pharmaceutical segment is mainly involved in manufacturing and sells of traditional Chinese medicines. The Company's products include kidney medicines, gynaecology and paediatrics medicines, contrast medium, orthopedics medicines, dermatologic medicines, hepatobiliary medicines and others. The Company mainly operates its businesses in the domestic market.

  • Revenue in HKD (TTM)3.01bn
  • Net income in HKD920.46m
  • Incorporated2010
  • Employees3.18k
  • Location
    Consun Pharmaceutical Group Ltd71 Dongpeng Avenue, East SectionEconomic and Technological DevelopmentGuangzhou Luogang DistrictGUANGZHOU 510760ChinaCHN
  • Phone+86 2 082016888
  • Fax+86 2 082017468
  • Websitehttp://www.chinaconsun.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Ocumension Therapeutics341.48m-355.16m3.09bn477.00--1.03--9.05-0.5419-0.54190.52084.390.1032.402.48769,089.90-10.71-38.78-11.55-41.4758.2962.30-104.01-975.825.00--0.0055--54.99--5.68--319.66--
Cutia Therapeutics218.84m-577.04m4.28bn360.00--3.27--19.54-1.90-1.900.7194.300.12062.316.93734,356.40-31.81---35.82--50.33---263.68--4.82--0.1818--1,110.83---253.30------
Jiangsu Recbio Technology Co Ltd0.00-603.67m4.30bn507.00--4.63-----1.26-1.260.001.920.00----0.00-25.33---32.84----------0.9619-60.960.4548------20.86------
Beijing Luzhu Biotechnology Co Ltd0.00-308.07m4.52bn148.00--4.38-----1.52-1.520.005.130.00----0.00-23.80---25.44----------5.91--0.0296------65.62------
Shandong Boan Biotechnology Co Ltd792.18m68.02m4.89bn813.0068.373.0333.866.170.13340.13341.563.010.30691.102.60974,387.102.63--3.43--74.10--8.59--1.034.010.3224--19.80--64.02------
Sihuan Pharmaceutical Holdings Group Ltd1.93bn-41.60m5.03bn2.65k--1.03--2.61-0.0045-0.00450.2080.5220.15060.96411.98672,300.30-1.77-6.85-2.68-9.1065.9175.81-11.78-36.231.52-1.390.181---14.70-8.6097.23--0.9325--
Consun Pharmaceutical Group Ltd3.01bn920.46m5.09bn3.18k5.281.255.051.691.141.143.744.820.52092.0011.77963,936.6015.9712.0423.2419.2574.2274.5530.6624.892.80--0.114440.8410.717.0314.8811.01-22.9318.43
AIM Vaccine Co Ltd1.30bn-1.31bn5.12bn1.56k--1.33--3.93-1.08-1.081.083.180.14620.63251.10802,448.00-22.69---37.16--72.34---155.22--0.6836-6.610.3437---6.06---307.07------
Shanghai Fudan-Zhangjiang Bio-Pharm. Co809.99m121.78m5.72bn948.0015.230.7035--7.060.11560.11560.76162.500.25041.261.35854,424.103.757.034.669.0591.2592.1714.9717.263.78--0.005239.16-17.502.78-21.28-0.632620.49--
Tong Ren Tang Technologies Co Ltd7.57bn716.19m6.19bn4.01k8.640.79224.320.81740.55920.55925.916.100.50260.98815.221,845,461.007.427.6811.6912.3240.9743.5014.7616.112.30--0.196839.9413.046.011.25-2.73-22.26-0.0089
Beijing Tong Ren Tang Chinese Medicine1.38bn494.14m6.29bn779.0012.741.6510.184.570.59030.59031.644.550.32840.35543.621,725,133.0012.7216.7114.0918.7572.0669.8838.7240.729.55--0.032768.87-11.910.1459-16.33-1.43-16.307.49
China Shineway Pharmaceutical Group Ltd4.63bn1.22bn6.50bn3.44k4.880.80514.671.401.611.616.139.760.44761.285.261,346,646.0011.768.0315.479.7775.2174.5526.2717.873.14--0.045736.2914.3211.9434.1413.890.639612.88
Yichang Hec Changjiang Pharmactcl Co Ltd6.10bn1.81bn7.21bn4.89k3.970.75583.421.182.062.066.9310.840.42722.503.571,320,291.0011.698.0317.2711.8178.9079.9727.3720.801.9325.510.212615.8168.0820.182,501.2416.15-11.50--
Everest Medicines Ltd460.62m-1.16bn7.45bn520.00--1.51--16.17-3.60-3.601.4315.130.07565.233.221,066,239.00-19.03-30.52-20.21-33.1475.74---251.64-5,745.254.62--0.1119--884.46---241.50--4.65--
Data as of Sep 20 2024. Currency figures normalised to Consun Pharmaceutical Group Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

6.55%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 04 Sep 202420.85m2.47%
Dimensional Fund Advisors LPas of 30 Jun 202411.27m1.33%
Fidelity Management & Research Co. LLCas of 31 Jul 202411.07m1.31%
Norges Bank Investment Managementas of 31 Dec 20234.24m0.50%
AllianceBernstein Ltd.as of 30 Jun 20243.09m0.37%
Fidelity Investments Canada ULCas of 31 Jul 20241.69m0.20%
Thrivent Asset Management LLCas of 28 Jun 2024912.00k0.11%
Quoniam Asset Management GmbHas of 30 Sep 2023793.00k0.09%
Fullgoal Fund Management Co., Ltd.as of 31 Dec 2023731.00k0.09%
Mackenzie Investments Corp. (United States)as of 30 Jun 2024650.82k0.08%
More ▼
Data from 31 Dec 2023 - 11 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.